

Date: 2nd May, 2023

To, The Manager, Department of Corporate Services, BSE Limited P. J. Towers, Dalal Street, Fort, Mumbai - 400 001 BSE Scrip Code: 533573	To, National Stock Exchange of India Limited Listing Department, Exchange Plaza, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051 NSE Symbol: APLLTD
--	---

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations, 2015”)

We would like to inform the exchange that based on the recommendation of Nomination and Remuneration Committee and the Board of Directors, the shareholders of the Company at their 12th Annual General Meeting of the Company held on 11th November, 2022 had approved the re-appointment of Mr. Shaunak Amin (DIN: 00245523) as Managing Director of the Company liable to retire by rotation for a period of 5 years w.e.f. 2nd May, 2023.

The proceedings of the aforesaid Annual General Meeting were submitted with the Stock exchanges on 11th November, 2022.

In this regard, we hereby declare that Mr. Shaunak Amin is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.

The detailed disclosure pursuant to Regulation 30(2) of Listing Regulations, 2015 read with SEBI Circular CIR/CFD/CMD/4/2015 dated 9th September, 2015 is enclosed herewith as Annexure - A.

We request you to kindly take the same on record.

Thanking you,
Yours faithfully,

For Alembic Pharmaceuticals Limited

Manisha Saraf
Company Secretary

Encl.: As above

ALEMBIC PHARMACEUTICALS LIMITED

Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) read with SEBI Circular CIR/CFD/CMD/4/2015 dated 9th September, 2015:

Sr. No.	Disclosure requirements	Details of Mr. Shaunak Chirayu Amin
1	Reason for change	Re-appointment
2	Date of appointment/ cessation –(as applicable) & term of appointment	2 nd May, 2023 Term of Appointment: 5 years w.e.f 2 nd May, 2023
3	Brief Profile (in case of appointment)	Mr. Shaunak Amin has been a Director in the Company since 2013 and was appointed as Joint Managing Director in April, 2015 and thereafter Managing Director in April, 2016. Mr. Shaunak Amin is heading India Formulations Business of the Company. He also serves as a Managing director on the board of Shreno Limited and director on the board of Incozen Therapeutics Private Limited.
4	Disclosure of relationships between directors	Mr. Shaunak Amin is son of Mr. Chirayu Amin, Chairman and CEO of the Company and brother of Mr. Pranav Amin, Managing Director of the Company.

ALEMBIC PHARMACEUTICALS LIMITED